A Prospective Non-Interventional Study to Assess Long-term Effectiveness of Zomacton® and Factors Affecting Adherence in Patients With Growth Hormone Deficiency or Growth Retardation Due to Ullrich-Turner Syndrome
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Somatrogon (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Acronyms RAZANT
- Sponsors Ferring Pharmaceuticals
- 23 Feb 2018 Planned initiation date changed from 15 Feb 2018 to 31 Mar 2018.
- 07 Feb 2018 Planned initiation date changed from 15 Dec 2017 to 15 Feb 2018.
- 05 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 15 Dec 2017.